stockrow
Friday 6 November 2026
Export COGT’s income statement to Excel — free account
Cogent Biosciences, Inc.
COGT Healthcare Biotechnology
- EPS
- +1.89%
- Free cash flow
- −42.0%
Quarter to June 2026, against a year earlier
31.60
2.02
+6.83%
Follow COGT
Alert me
Cogent Biosciences, Inc. (COGT) P/S ratio
As of 6 November 2026, Cogent Biosciences, Inc. (COGT) trades at a P/S ratio of 233×. Over the past ten years it has ranged from 0.4× (December 2019) to 316× (August 2026); the current reading is higher than 94% of that period. That is above the Biotechnology industry median of 9.4× and above the Healthcare sector median of 3.5×.
P/S ratio, daily
Embed this chart
Annual newest first
| Period | P/S ratio | Change |
|---|---|---|
| FY2020 | 5.4× | 450.88% |
| FY2019 | 1.0× | (91.33%) |
| FY2018 | 11.3× | (16.75%) |
| FY2017 | 13.5× | 0.00% |
| FY2016 | 13.5× | 0.00% |
| FY2015 | 13.5× | — |
Quarterly newest first
| Period | P/S ratio | Change |
|---|---|---|
| Sep 2020 | 4.0× | 564.01% |
| Jun 2020 | 0.6× | 27.71% |
| Mar 2020 | 0.5× | (51.87%) |
| Dec 2019 | 1.0× | (2.65%) |
| 11 more quarters | Free account |
Against its own ten years
Low 0.4×
High 316×
Ten-year median
24.4×
Current reading's percentile
94
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| ERAS Erasca, Inc. compare | n/m |
| MANE Veradermics Incorporated compare | n/m |
| KOD Kodiak Sciences Inc. compare | n/m |
| PTCT PTC Therapeutics, Inc. compare | 4.7× |
| TVTX Travere Therapeutics, Inc. compare | 7.2× |
| SRRK Scholar Rock Holding Corporation compare | 130× |
| CRSP CRISPR Therapeutics AG compare | 192× |
| COGT Cogent Biosciences, Inc. | 233× |
| DNTH Dianthus Therapeutics, Inc. compare | 1,823× |
| Biotechnology industry median | 9.4× |
| Healthcare sector median | 3.5× |
| Market median | 1.9× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on COGT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement